Eloxx Pharmaceuticals posts deeper operating and net losses on both reporting windows, with diluted per-share loss narrowing

Bottom line

- For the three-month reporting period covered by this filing, Eloxx Pharmaceuticals, Inc. 66 per diluted share USD/SHARES — all three line items negative, consistent with a clinical-stage biotechnology issuer that has incurred significant operating losses since inception. 48 per diluted share USD/SHARES, also all negative.

45 per diluted share USD/SHARES increased to a smaller per-share loss in the current quarter, with the transition remaining loss to loss on both windows. 39 per diluted share USD/SHARES increased to a smaller per-share loss in the current year-to-date, with the transition remaining loss to loss on both windows. - Management frames the period through forward-looking cautionary language embedded in the Special Note Regarding Forward-Looking Statements, emphasizing dependence on the lead product candidate, the need for additional funding to continue as a going concern, and the possibility that capital, listing, regulatory, or clinical milestones may not be achieved on the expected timetable.

- Management attributes the persistence of losses to the company’s clinical-stage biotechnology status, noting that Eloxx has incurred significant operating losses since inception and anticipates substantial operating losses for the foreseeable future. - The authorized directions imply a pattern in which top-line operating and net losses widen year over year in absolute dollars on both reporting windows, while the diluted per-share loss narrows — a shape consistent with a share count that has grown relative to the prior-year comparative, though the underlying driver of the share-count movement is not stated in the filing evidence.

- the filing text does not present any offsetting positive operating metric, segment profit, or non-recurring gain that would contradict the loss-to-loss transitions observed across both comparative windows. - The specific components of operating expense, the cash runway figure, and the post-balance-sheet equity issuance terms referenced in the cited note on Stockholders’ Deficit are not within the FACT catalog available to this section. - The filing evidence does not attribute this change to any single cause.

- The filing evidence contains no peer or industry comparison. - For additional Lizely Finance context on interim filings that moved from loss to loss on a per-share basis, the UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows insight offers a comparable structural read; readers seeking a profit-side interim template may also reference the ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows insight.

Financial performance

Reported facts - Eloxx remained loss-making on both operating and net-income measures in the three-month reporting period and the six-month year-to-date period. Diluted earnings per share was also negative on both bases: -$0.66 per diluted share and -$1.48 per diluted share. - Relative to the corresponding prior-year periods, operating loss widened to -$4,450,000 from -$1,582,000 for the quarter and to -$8,246,000 from -$2,804,000 for the year-to-date period. - Net loss attributable to the parent widened to -$4,502,000 from -$1,891,000 for the quarter and to -$8,256,000 from -$3,600,000 for the year-to-date period. - Diluted earnings per share improved directionally from a loss to a loss. The current quarter result was -$0.66 per diluted share, compared with -$5.45 per diluted share in the prior-year quarter. For the year-to-date comparison, the results were -$1.48 per diluted share and -$10.39 per diluted share, respectively.

Management explanations - Management describes Eloxx as a clinical-stage biopharmaceutical company developing product candidates designed to modulate the ribosome and promote readthrough of premature stop codons. It also states that the company has incurred significant operating losses since inception and expects substantial operating losses to continue for the foreseeable future. - The filing identifies lead-product development, clinical-trial progress, regulatory outcomes, intellectual-property protection, and continuing public-company obligations as material business risks. These statements provide context for the ongoing loss profile but do not quantify the contribution of any individual item to the reported changes. - The cited note concerning license agreements, collaboration advances, legal matters, and other contingencies may be relevant to the accounting context, but the filing evidence does not provide a complete bridge from those items to the reported loss movements.

Analyst inference - The principal performance signal is persistent unprofitability rather than a transition to profitability. The latest quarter and year-to-date results remain losses, while operating loss and parent-attributable net loss widened relative to the corresponding prior-year periods. - The company’s clinical-stage development model supports reading the reported losses as part of an ongoing development and operating profile, rather than as evidence of a near-term earnings inflection.

Counter-evidence - Diluted earnings per share moved in a less negative direction year over year, providing a limited offset to the broader deterioration in operating loss and net loss. - Management’s statement that substantial operating losses will continue is forward-looking commentary, not a quantified financial outcome.

QOQ - The filing evidence does not authorize a quarter-over-quarter comparison for these performance measures. A sequential analysis would require information beyond the cited current and prior-year data.

GUIDANCE - Management expects substantial operating losses to continue for the foreseeable future, but the filing does not provide a quantified financial forecast, target, or formal earnings guidance in the cited material. - No forward-looking statement in this section should be treated as a forecast of a specific result.

EXPECTATIONS - The most defensible baseline is continued operating and net losses, with the year-over-year widening of operating loss and net loss providing the clearest reported comparison. Readers should distinguish the company’s broad loss profile from the limited improvement in diluted earnings per share. - The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence does not attribute this change to any single cause.

Operating drivers and segments

- Operating Income (Loss) for the three-month reporting period was -$4,450,000 USD, a loss rather than a profit, and the corresponding prior-year three-month result was -$1,582,000 USD, also a loss. The authorized quarter-over-quarter direction is decrease, with the current period deepening from a loss to a larger loss. - Operating Income (Loss) for the six-month year-to-date period was -$8,246,000 USD, again a loss rather than a profit, versus -$2,804,000 USD for the prior-year six-month comparative, also a loss. The authorized half-year direction is decrease, with the current period widening from a loss to a larger loss. - The company operates as a single clinical-stage pharmaceutical business centered on its lead candidate, and the filing does not break out revenue or operating results across multiple operating segments; segment-by-segment margin commentary is therefore not available from the filing evidence.

- Management frames the operating performance discussion through the lens of a single-product pipeline, repeatedly emphasizing that the company is "heavily dependent on the success of our lead product candidate, exaluren," and warning that failure or delay at the trial stage could materially harm the business. - Forward-looking narrative in the filing is broad: statements reference future results of operations, the timing of trials, regulatory communications, projected costs, and the company's ability to obtain capital necessary to fund operations and continue as a going concern, as set out under Item 2 and the Special Note Regarding Forward-Looking Statements. - Management does not, in the cited narrative, attribute the quarter-to-quarter or year-to-date widening of the operating loss to any single line item such as research and development spend, general and administrative costs, or share-based payment expense. Independent readers therefore cannot, from management's own words, isolate which cost bucket drove the deterioration.

<prose> The operating picture presented by Eloxx Pharmaceuticals, Inc. in this 10-Q for period-ended-2026-06-30 (accession 0001193125-26-344964, CIK 0001035354, ticker ELOX) is uniformly one of loss expansion on both reporting windows. On the three-month view, the period ended the three months ended June 30, 2026 produced an Operating Income (Loss) of -$4,450,000 USD, deeper than the -$1,582,000 USD loss recorded for the prior-year three-month comparative period the three months ended June 30, 2025. On the year-to-date view, the six-month period ended the six months ended June 30, 2026 generated an Operating Income (Loss) of -$8,246,000 USD, wider than the -$2,804,000 USD loss reported for the six months ended June 30, 2025. Both authorized transitions are loss to loss, and both authorized directions are decrease, so the only fair qualitative characterization is a loss that has grown rather than narrowed.

Because the company is described in the filing as a single clinical-stage entity whose value hinges on exaluren, there is no segment-level evidence to weigh against management's narrative; the report carries one economic engine, not several. Readers looking for a margin mix between, say, research and development versus general and administrative cost cannot derive it from this filing's quoted excerpt, and The filing evidence contains no peer or industry comparison. applies because the filing evidence offers no benchmark against which to size the loss.

On the management side, the Special Note Regarding Forward-Looking Statements, expanded under Item 6 and cross-referenced to Item 1A, casts the deterioration as a function of pipeline risk and capital-raising risk rather than as a cost-control failure, but it never ties the specific change in operating result to a named driver. As a result, The filing evidence does not attribute this change to any single cause. is the only honest statement about why the operating loss widened; any attempt to pin the move on a particular expense category, including the share-based payment increases referenced in Note 7 or the contingent items discussed in Note 6, would exceed what management actually asserts. Independent analysts are therefore left with directional facts — a deeper operating loss on both windows — and a management commentary that acknowledges risk but declines to quantify causation.

Cash flow and capital

- Operating cash burn was negative on both halves of the year-to-date comparison. Net Cash Provided by (Used in) Operating Activities was -$10,242,000 USD for the six months ended the six months ended June 30, 2026, against -$549,000 USD for the prior-year comparative period. The authorized direction for this line is decrease; the current six-month period sits deeper in negative territory than the prior-year window, even though both halves continue to show net cash usage rather than generation.

- Financing cash flow remained positive on both year-to-date windows. Net Cash Provided by (Used in) Financing Activities was $67,417,000 USD for the six months ended June 30, 2026 and $1,010,000 USD for the six months ended June 30, 2025. The authorized direction is increase, so the current six-month figure is higher than the prior-year comparative, and the period continued to be a net source of cash rather than a use.

- The composition of the balance sheet at the reporting date is light. Cash and Cash Equivalents, at Carrying Value was $61,960,000 USD as of the balance sheet date of June 30, 2026, and Accounts Payable, Current was $3,028,000 USD at the same instant. Management discloses that the cash balance as of June the balance sheet date of June 30, 2026 includes net proceeds from a public offering described in Note 7 "Stockholders' Deficit", which the company identifies as a central piece of its near-term runway.

- Management's going-concern framing links the cash position to forward funding needs. The narrative states that the company expects to continue incurring net losses and negative operating cash flows for the foreseeable future, has historically financed operations through equity sales, license and collaboration agreements, and debt, and may need to raise additional capital to fund operations. The same liquidity paragraph asserts that existing cash and cash equivalents will be sufficient to maintain current and planned operations for at least the next twelve months following the filing of this Quarterly Report on Form 10-Q.

- Management also flags a structural shift in the equity base: a one-for-eleven reverse stock split was effected in May of the prior year, with all share and per-share amounts retroactively adjusted, and stockholders entitled to fractional shares received cash in lieu of those fractions. The Almirall License Agreement performance obligation ended in November of the cited year, although milestone and royalty potential remains, with development and sales milestones cited at up to approximately a multimillion-dollar ceiling.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

Peer and historical context

- Reading the figures filed by Eloxx Pharmaceuticals, Inc. for the three-month reporting period the three months ended June 30, 2026 alongside the prior-year comparative window, the bottom line remained in the loss column on both sides. Net Income (Loss) Attributable to Parent came in at -$4,502,000 USD for the current quarter and -$1,891,000 USD for the three months ended June 30, 2025. Operating Income (Loss) tracked a similar pattern, registering -$4,450,000 USD against -$1,582,000 USD in the year-ago window, with the direction of change on both lines pointing lower in the more recent quarter.

- The six-month year-to-date view broadens the comparison. Net Income (Loss) Attributable to Parent was -$8,256,000 USD for the six months ended June 30, 2026 versus -$3,600,000 USD for the six months ended June 30, 2025, while Operating Income (Loss) printed at -$8,246,000 USD against -$2,804,000 USD in the prior-year window. Both comparisons show a larger loss rather than a profit on the current six-month basis, with operating-line deterioration tracking the net result.

- Cash usage widened as well. Net Cash Provided by (Used in) Operating Activities was -$10,242,000 USD for the six months ended June 30, 2026 and -$549,000 USD for the six months ended June 30, 2025, both negative, with the current six-month outflow running deeper than the prior year. Management attributes the working-capital backdrop to the same cost structure discussed throughout Item 7, noting the Company has historically funded itself through equity sales, license and collaboration agreements, debt securities and grants.

- Per-share figures reinforce the qualitative read. Diluted Earnings Per Share sits as a loss on the current three-month period against a loss in the prior-year quarter, and a loss on the current six-month period against a loss in the prior-year six-month period, in each case moving in the authorized direction.

The filing evidence does not attribute this change to any single cause.

- No peer or industry benchmark is presented in the filing, so cross-company positioning cannot be drawn from this evidence. The filing evidence contains no peer or industry comparison.

- For context on how other small-cap healthcare issuers presented interim results against their own year-ago windows, the write-up of REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing shows a contrasting profit-to-profit pattern on both windows.

Scenario analysis

The base path for Eloxx Pharmaceuticals, Inc. (ELOX) on the windows reported under 10-Q for period-ended-2026-06-30 keeps the company in a net loss position on both the three- and six-month views. Reported Net Income (Loss) Attributable to Parent for the current three-month period of the three months ended June 30, 2026 was -$4,502,000, a loss rather than a profit, while the prior-year comparative for the three-month period of the three months ended June 30, 2025 was -$1,891,000, also a loss. The year-to-date view moves in the same direction: the current six-month period of the six months ended June 30, 2026 shows Net Income (Loss) Attributable to Parent of -$8,256,000, a loss, against the prior-year comparative for the six-month period of the six months ended June 30, 2025 of -$3,600,000, a loss as well, with the loss widening year over year on the six-month window. The filing evidence does not attribute this change to any single cause.

A constructive path would require the loss on both windows to stop widening and begin narrowing, ideally with a route toward break-even or a profit outcome. Within the filing evidence, no such transition is yet visible: the three-month comparison is authorized as a loss-to-loss movement, the six-month comparison is authorized as a loss-to-loss movement, and the directional authorization for Net Income (Loss) Attributable to Parent on both windows is a decrease, meaning the loss is wider than the prior period rather than narrower. Upside catalysts in the cited narrative are contingent and unquantified, including milestone and royalty eligibility tied to the Almirall arrangement and potential future funding from the Cystic Fibrosis Foundation, but the filing records no license and service revenue from the Almirall License Agreement for the three and six months ended and no funds received from the CFF in those same windows. The filing evidence does not attribute this change to any single cause.

A more adverse path would see the loss on both reporting windows deepen further and liquidity tighten. The current evidence already shows Net Income (Loss) Attributable to Parent as a loss on the three-month view of the three months ended June 30, 2026 against a prior-year loss for the three months ended June 30, 2025, and a loss on the six-month view of the six months ended June 30, 2026 against a prior-year loss for the six months ended June 30, 2025, with the six-month loss wider than the prior period. The cited Liquidity and Capital Resources discussion in Item 7 and the debt disclosures in the cited note describe reliance on non-interest-bearing bridge funding from Domicilium and prior Hercules obligations, with imputed interest recorded and repayments against the Royalty and Revenue Sharing Agreement referenced in the cited note on contingencies. The filing evidence does not attribute this change to any single cause. The Item 1A risk-factor discussion and Item 4 legal-proceedings framing are the structural placeholders where any incremental adverse developments would be expected to surface, but no specific incremental driver is named in the quoted evidence.

A cross-filing reference point on earnings-window transitions is offered by the related write-up on ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows, which contrasts with the loss-to-loss path described here.

Risks and what to watch

- The headline net loss widened on both reported windows versus the prior-year comparative periods, using only the authorized framing the catalog permits. For -$8,256,000 the move was a deeper loss than -$3,600,000, and for -$4,502,000 the move was a deeper loss than -$1,891,000, with each transition described as a loss-to-loss decrease in Net Income (Loss) Attributable to Parent. - Operating Income (Loss) tracked the same shape: a loss that grew larger on both the six-month and three-month windows against the prior-year comparative periods, in each case loss-to-loss, so the bottom-line deterioration is not contradicted by the operating line.

- The only counter-signal in the Authorized Comparisons is on the financing side, where Net Cash Provided by (Used in) Financing Activities moved higher year over year on the six-month window, while Net Cash Provided by (Used in) Operating Activities moved lower on the same window. The reader should weigh the deeper operating and net losses against that financing uplift rather than treat either in isolation. - Management's narrative introduces several risk anchors that frame the next period but are not quantified in the filing.

Under the Almirall License Agreement, Almirall declined to exercise its option for continued research and development services, and the Company recorded no license and service revenue from that arrangement on either window, so any future milestone or royalty inflow remains contingent on a partner's continued commitment. - The Cystic Fibrosis Foundation advances remain on the balance sheet with repayment triggers tied to a successful commercialization of exaluren or any derivative product; no funds moved in either direction during the period, and the related embedded derivatives were carried at zero after the CFF Amendment.

- The Israel Innovation Authority royalty commitment creates a low single-digit royalty obligation on future end-customer sales of IIA-funded product candidates, with the contingent obligation inclusive of accrued interest at period-end. If sales never materialize, neither royalties nor grant repayment is triggered, leaving the obligation contingent rather than current. - Forward-looking-statement and risk-factor discussion sits in Item 1A and the broader Part II items, while legal proceedings and other information are addressed in Item 1 and Item 4, and controls and market-risk disclosures appear in Item 3; readers should treat those as the primary risk repositories rather than relying solely on the income-statement movement.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry benchmark for this loss trajectory, so cross-company context such as the REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing insight illustrates only a different reporting pattern, not a comparable benchmark. The filing evidence contains no peer or industry comparison.

- The filing evidence does not disclose segment-level detail for this dimension. - Metrics to watch next period: the Net Income (Loss) Attributable to Parent on both the three-month and six-month windows, the Operating Income (Loss) trajectory, the cash flow split between operating and financing activities, any resumption or further silence on Almirall license and service revenue, the balance and terms of the Cystic Fibrosis Foundation advances, and any change in the IIA contingent obligation as development activity continues.